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Health-care professionals (HCPs) involved in genetic/genomic 
medicine will often become aware that patients have relatives 
who are at risk. HCPs will generally encourage patients to share 
relevant genetic information, especially if risk-reducing inter-
vention is available.1 But to what extent do HCPs have a respon-
sibility to ensure that relatives are informed?
Family communication studies have shown most patients 
tell—or intend to tell—at-risk relatives (herein referred to as 
“relatives”), but some do not, for reasons including guilt and 
fearing blame, poor relationships, difficulty finding the right 
time, and perceived inability to communicate accurately.2–5 
Moreover, research suggests that patients perceive more clearly 
defined responsibilities to tell first-degree relatives than wider 
family, and that relationship closeness, rather than intervention 
availability, often drives communication.6,7
Patients may also be unsure of HCPs’ responsibility. Of 
patients with Lynch syndrome, 56% (45/80) thought that 
HCPs, rather than themselves, should inform relatives, and, 
consequently, 12% failed to communicate risk.7 Some patients 
have reported that HCPs did not tell them sharing was impor-
tant or prompt them to share.8 These findings are important 
because noncommunication or delayed communication can 
have serious ramifications—a study of 30 parents with Lynch 
syndrome showed that several postponed communication with 
offspring, some of whom later developed a preventable cancer.9
When patients have refused to communicate to relatives or 
when HCPs are unsure whether they have done so, HCPs face 
conflicting duties to respect patient confidentiality, privacy, and 
autonomy but also prevent possible harm and promote benefit 
to relatives. Internationally, guidelines assert that confidential-
ity is not absolute and give HCPs the “privilege” of breaching 
it under certain circumstances.10 UK General Medical Council 
guidelines11 state that HCPs can share information without 
explicit patient consent when the benefit of disclosure out-
weighs the interest of the public and the patient in keeping the 
information confidential and when nondisclosure puts others 
at risk of death or serious harm.
Guidelines focus mainly on situations when patients refuse 
consent. What HCPs can and should do when they are sim-
ply unsure whether communication has happened is unclear. 
Guidelines also take individual confidentiality as the default 
position; breaches are acceptable only under exceptional cir-
cumstances. Parker and Lucassen12 have argued that HCPs could 
instead err on the side of disclosure rather than confidence. 
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Purpose: The extent of the responsibility of health-care profession-
als (HCPs) to ensure that patients’ relatives are told of their risk is 
unclear. Current international guidelines take confidentiality to the 
individual patient as the default position, but some suggest that dis-
closure could be default and genetic information could be conceptu-
alized as familial.
Methods: Our systematic review and synthesis of 17 studies 
explored the attitudes of HCPs, patients, and the public regarding the 
extent of HCPs’ responsibility to relatives with respect to disclosure.
Results: Health-care professionals generally felt a responsibility to 
patients’ relatives but perceived a variety of reasons why it would be 
difficult to act on this responsibility. Public/patient views were more 
wide-ranging. Participants identified several competing and over-
lapping arguments for and against HCP disclosure: guidelines do 
not permit/mandate it, privacy, medical benefit, impact on family 
dynamics, quality of communication, and respecting autonomy.
Conclusion: We argue that HCPs can sometimes share genetic 
information without breaching confidentiality and that they could 
factor into their considerations the potential harm to family dynam-
ics of nondisclosure. However, we need more nuanced research about 
their responsibilities to relatives, particularly as genomic tests are 
used more frequently in clinical practice.
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They propose a “joint account” model of confidentiality, in 
which patients’ clinical information (e.g., their identity and test 
result/diagnosis) is conceptualized as confidential, but genetic 
information (e.g., the mutation) is conceptualized as familial 
information, the sharing of which would not be a breach of 
confidence. They urge HCPs to take disclosure as the default 
option and identify reasons that would justify excluding other 
“account holders” from what is essentially their information. 
This model is the basis of current British Society for Genetic 
Medicine confidentiality guidelines.13 Similarly to Parker and 
Lucassen,12 Gilbar14 argues that HCPs should move away from 
individualistic notions of autonomy and toward a relational 
approach. This approach emphasizes that people develop 
autonomy through social embededness and engagement with 
others, and that people have an interest in maintaining familial 
relationships.
Findings from interventional studies show that when HCPs 
take active steps to ensure that information has been com-
municated (e.g., by writing directly to relatives, inviting them 
to counseling and educational sessions, or confirming at fol-
low-up appointments that patients have told relatives), testing 
uptake among relatives at risk for Lynch syndrome and heredi-
tary breast/ovarian cancer has significantly increased.15–17 Other 
studies, with relatives contacted through cancer registries, have 
shown that they appreciate such contact.18,19
Little research has been done on the attitudes of HCPs, 
patients, and the public on the responsibility of HCPs to ensure 
that relatives, including those who are not their patients, are 
informed. To identify consensus and contention regarding the 
issue, a systematic analysis of the research conducted thus far 
is needed. The need is particularly pressing, first, because array 
comparative genomic hybridization, whole-exome sequencing, 
and whole-genome sequencing are rapidly replacing more 
targeted genetic testing in the clinic. Because these tests pro-
duce information of greater volume and complexity, findings 
in patients that also predict ill health in their relatives are likely 
to increase.20 Second, HCPs whose specialties lie outside genet-
ics and who will not necessarily have experience managing 
families are beginning to incorporate genetic and genomic tests 
into practice.20 We therefore conducted a systematic review and 
mixed-methods research synthesis about perceptions of HCPs’ 
responsibility to relatives and views on the role of HCPs in 
disclosure.
MATERIALS AND METHODS
Search strategy and study appraisal
Using systematic review guidelines,21 we searched for empiri-
cal research studies using the databases, keywords, and inclu-
sion/exclusion criteria shown in Figure 1. We excluded 
research exploring communication between family members 
because much has already been written about the topic. The 
17 papers thus retrieved (HCPs, n = 8; HCP/patients, n = 1; 
patients, n = 6; the public, n = 2) are detailed in Table 1. Three 
with patients22–24 had only small relevant sections. Most studies 
focused on inherited cancer risks, often classified as actionable 
because of surveillance, chemoprevention, or risk-reducing 
surgical options.
S.D., A.F. and A.L. independently appraised the quality of 
each paper25 and agreed on its inclusion. A general limitation 
was that study authors often used hypothetical scenarios to 
gather views but these might not represent real-life actions. 
Another limitation was that, except for a few,26–28 most asked 
about disclosure when patients explicitly refused consent rather 
than when HCPs were unsure whether patients had disclosed, 
and so our synthesis focuses more on the former. A third limita-
tion was that many studies used surveys, which provide useful 
generalizable data but do not always allow participants to dis-
cuss complex views in detail.
Heterogeneity in studies
Our study population was heterogeneous, originating from 
10 countries (United States, United Kingdom, Australia, 
Israel, Norway, Sweden, Canada, Slovenia, Turkey, and the 
Netherlands) and including a variety of participant groups. 
For example, four HCP studies involved HCPs working 
outside genetics. Participants’ views may have been influ-
enced by differences in culture and practice between and 
Figure 1 PRISMA flow diagram.
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Records after duplicates removed
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clinical setting from 1995-present.
Excluded: research about communication between family members;
commentaries.
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Table 1 Detail of included studies
Author/year Location Participants Risks discussed Design
How disclosure 
dilemmas were 
conceptualized
How authors asked about 
responsibility
HCP studies
   Barnoy and 
Tabak37
Israel: Tel Aviv 
University, 
nursing dept.
73 nurses Breast cancer, 
Huntington 
disease, and fragile 
X
Quantitative 
opinion survey
Autonomy vs. being 
paternalistic (i.e., 
disclosing)
Whether they should take 
steps to inform the patient’s 
family if the patient refuses 
to do so
  Clarke et al.33 UK: country-wide 
genetics depts. 
and Australia: 
location 
undisclosed
12 regional 
genetics 
centers: 
38,677 cases 
discussed
Any genetic risk Prospective 
survey
Autonomy vs. 
preventing harm to 
others
Frequency with which HCPs 
become concerned about the 
refusal of patients to disclose 
information to relatives; 
circumstances in which these 
situations arise; and the 
actions taken by HCPs
  Dugan et al.34 USA: country-
wide
259 genetic 
counselors
Any genetic risk Retrospective 
quantitative 
survey
Privacy and 
autonomy vs. 
preventing harm 
to and promoting 
benefit for relative
Whether genetic counselors 
have an obligation to at-risk 
relatives, and disclose without 
consent
  Falk et al.35 USA: country-
wide
206 medical 
geneticists
Any genetic risk Retrospective 
quantitative 
survey
Privacy and 
autonomy vs. 
preventing harm 
to and promoting 
benefit for relative
Whether clinical geneticists 
have an obligation to at-risk 
relatives, and disclose without 
consent
  Erde et al.36 USA: New Jersey, 
family doctors
162 doctors Unspecified 
autosomal 
dominant risk
Quantitative 
opinion survey
Confidentiality vs. 
duty to warn
Willingness or unwillingness 
to inform patients’ relatives
  Gilbar41 UK: country-
wide, various 
depts.
10 GPs; 4 
genetics; 4 
cardiologist; 3 
oncologists
Any genetic risk Legal analysis 
and qualitative 
interviews
Confidentiality, 
privacy, intimacy, 
and autonomy 
(individual and 
relational)
Attitude to confidentiality 
and disclosure to relatives, 
decisions in dilemmas, and 
reactions of patients/relatives
   Klemenc-Ketiš, 
and Peterlin38
Slovenia: 
country-wide, 
family doctors
271 doctors Hypertrophic 
obstructive 
cardiomyopathy
Quantitative 
opinion survey
Privacy vs. duty to 
warn
Willingness to inform 
patients’ relative
  Stol et al.26 The Netherlands: 
country-wide 
genetics depts.
9 clinical 
geneticists 
(one from 
each Dutch 
genetics 
centre)
Hereditary cancer 
predispositions
Qualitative 
interviews
Duty to warn and 
prevention of harm 
vs. respecting a 
relative’s wish not 
to be informed or 
their right not to 
know
Dissemination of 
information to relatives 
when patient does not 
object; whom they 
consider the patient; and 
perceived duty to warn 
relatives themselves.
HCP/patient study
   Akpinar and 
Ersoy39
Turkey: Kocaeli 
ob/gyn and 
pediatrics depts.
15 doctors; 
104 parents/
patients (67 
ob/gyn; 37 
pediatrics)
Translocations Quantitative 
opinion survey
Autonomy 
and privacy vs. 
obligations of the 
state in terms of 
social justice and 
medical benefit to 
relatives
Whether a doctor should 
notify patient’s spouse about 
a risk; whether the doctor 
has a responsibility to warn 
siblings
Table 1 Continued on next page
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within these groups/countries, e.g., health-care systems 
(insurance-based versus free-at-the-point-of-use) and 
social attitudes toward genetic conditions.29 Across the 10 
countries, guidelines/laws are generally similar in permit-
ting disclosure without consent in narrow circumstances 
(see Supplementary Table S1 online). Notable differences 
Patient studies
   Benkendorf et al.22 USA: 
Georgetown/
Washington 
cancer centers, 
ob/gyn depts., 
and genetics 
clinics
238 First-degree relative 
with breast/ovarian 
cancer
Quantitative 
opinion survey
Confidentiality 
and autonomy vs. 
responsibility to 
warn relatives
Whether HCPs should be 
able to disclose the results 
of genetic tests for HBOC to 
immediate relatives without 
written consent
  Forrest et al.23 UK: Aberdeen 
genetics service
56 21 at risk for 
HBOC; 16 pre-
symptomatic HD
Qualitative 
interviews
Confidentiality/
autonomy vs. 
preventing harm
To whom the responsibility to 
inform relatives belongs
   Gilbar and 
Barnoy30
Israel: country-
wide outpatient 
clinics that offer 
genetic services
564 Susceptibility 
testing: 282 
hereditary cancers 
and  282 recessive 
early-onset 
conditions before/
during pregnancy
Quantitative 
opinion survey
Autonomy, privacy, 
and confidentiality 
vs. risk of physical 
harm to relatives and 
moral responsibility 
to them
Attitudes towards 12 
statements about the nature 
of genetic information:
  Kohut et al.27 Canada: Ontario 
cancer genetics 
dept.
105 Lynch syndrome 
mutation 
confirmed/
unconfirmed
Quantitative 
survey with 
qualitative 
component
Confidentiality, 
autonomy vs. burden 
on health service
Whether they would give 
permission for a genetic 
counselor or doctor to warn
  Pentz et al.28 USA: Houston, 
Texas, cancer 
center
80 Lynch syndrome 
mutation 
confirmed and 
their relatives
Qualitative 
interviews 
(subjected 
to content 
analysis, 
resulting in 
frequencies)
Confidentiality/
privacy and burden
on health-care
system vs. duty to 
warn
Perceptions of the duty to 
inform relatives
  Plantinga et al.24 USA: Baltimore, 
Maryland (various 
depts.)
597 Cystic fibrosis; 
sickle cell disease; 
colon cancer; 
breast cancer 
(affected and 
family history 
thereof)
Quantitative 
survey
Confidentiality, 
privacy, and 
discrimination
Views about doctors giving 
relatives information without 
permission
Public studies
  Lehmann et al.40 USA: Boston, 
Massachusetts
200 (Jewish 
women who 
face risk of 
BRCA)
HBOC Quantitative 
survey
Duty to 
maintain patient 
confidentiality and 
autonomy vs. duty 
to inform at-risk 
relatives
Whether a doctor should 
seek out and inform at-risk 
relatives against a patient’s 
wishes
  Wolff et al.31 Sweden: 
country-wide and 
Norway: Bergen
4,207 (Public 
and student 
samples)
Conditions varied 
by penetrance, 
treatability, and 
fatalness
Quantitative 
survey
Confidentiality vs. 
duty to warn
Whether they would want a 
doctor to contact and inform 
them even if their relative is 
against it
HBOC, hereditary breast/ovarian cancer; HCP, health-care professional; ob/gyn, obstetrics and gynecology.
Table 1 Continued
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are that some UK guidelines encourage HCPs to consider 
disclosure over confidence when appropriate,13 Israeli law 
requires hospital ethics committees to approve disclosure,30 
and Norwegian law completely disallows disclosure without 
patient consent.31 Guidelines/laws provide some context, but 
they are unlikely to completely shape professional practice 
norms or participants’ views. We attempt to make differen-
tiations when possible but, because of this heterogeneity, as 
well as the relatively small number of retrieved studies, the 
synthesis findings are tentative.
Data extraction and analysis
To create the synthesis, we, as per previous research,32 themat-
ically analyzed findings from each study. To do so, we listed 
each relevant concept discussed in each study (omitting, 
for example, views about disclosure to employers) and 
grouped similar concepts to create a thematic structure. 
S.D., A.F. and A.L. independently reviewed themes and scru-
tinized studies to explain variations and integrate “deviant 
cases” (those not fitting the general structure). Each head-
ing below represents a theme. Table 2 shows which studies 
raised each theme.
RESULTS
Terminology and definitions varied
“Nondisclosure” was conceptualized by Clarke et al. (United 
Kingdom/Australia)33 as the situation of a HCP thinking that a 
patient should disclose information to relatives (because failure 
to do so could lead to harm) but they seemed unlikely to disclose. 
Two US studies similarly described it as a patient’s refusal to 
notify relatives.34,35
Between and within studies, authors used varying phrases, 
including “responsibility to warn,”22,39 “duty to warn,”26-28,31,34-39 
“duty to inform,”28,30,40 “obligation to disclose,”33,37 “obligation to 
share,”34 and HCPs’ “right to disclose to relatives.”31 “Consent” 
and “permission” were also used interchangeably. There were 
no obvious differences in their application, but the variety of 
terms suggests possible limitations in how HCPs/researchers 
communicate with one another. None of the studies specified 
what “warning” and other nomenclature meant in practical 
terms. We therefore use “HCP disclosure” here to capture any 
way in which HCPs might be practically involved in inform-
ing relatives (e.g., via direct contact or other genetics centers or 
relatives’ general practitioner).
Patients/public: wide-ranging views
Except for one,31 studies were framed such that participants 
probably took patients’ rather than relatives’ perspectives and 
considered that HCPs would be sharing their information with-
out their consent.
In approximately half the studies, patients had unfavorable 
views of HCPs sharing information without consent. Patients 
in Israel30 undergoing testing for hereditary cancers and prena-
tal risks (n = 564) on average thought that HCPs had no right 
to disclose genetic information to relatives without consent. 
Patients in that study thought genetic information was familial 
but also personal. In fact, a minority (5.3%, n = 30) said they did 
not intend to share genetic tests results with family. However, 
no distinction was made between HCPs sharing general genetic 
information (e.g., the mutation) versus more personal infor-
mation (e.g., patients’ diagnosis or in whom the risk had been 
found).
Plantinga et al.24 also reported unfavorable views among 397 
patients (United States) affected by breast/colon cancer, sickle 
cell disease, or cystic fibrosis. Only approximately 30% said they 
“would not mind” HCPs giving specific information  (“medical 
information about me”) to relatives without permission and 
approximately 50% thought HCPs should be punished for 
doing so. In a US study with 238 women,22 when asked whether 
HCPs should be able to “disclose the results of genetic tests for 
hereditary breast/ovarian cancer” to immediate relatives with-
out written consent, 87% thought they should not. Another US 
study40 found similar views among the public (n = 200): less 
than one-quarter thought HCPs should seek out and inform 
relatives about risk and prevention options against patients’ 
wishes across three scenarios (Huntington disease (HD), breast 
cancer, and colon cancer).
Patients had somewhat more favorable views about HCP 
disclosure in three other studies. Of 105 patients (Canada),27 
most (55.8%) wanted HCPs to tell at-risk relatives without their 
permission. However, others said they would not have sought 
genetic counseling if they knew HCPs could inform without 
permission. Pentz et al. (United States)28 found that 76% of 80 
patients said “Yes” when asked whether it was permissible for 
HCPs to inform relatives. Very few patients added caveats such 
as “with permission.” They also thought patients and HCPs had 
a duty to inform relatives. In another study, with 104 patients 
(Turkey),39 who were given a hypothetical scenario, most 
(80.8%) disagreed that HCPs should respect a patients’ wishes 
to withhold information about a balanced translocation, and 
most agreed that HCPs should tell the spouse (84.6%) and sib-
lings (52.9%)—who were all at reproductive age and wanting 
children.
From the relative’s perspective
Only one study31 explicitly asked participants to take the 
 relative’s perspective (i.e., consider that a HCP is sharing 
information with them rather than about them). Slightly less 
than half of the 1,200 participants (Swedish public) said they 
would want a HCP to inform them against the related patient’s 
wishes of a fatal, nontreatable condition with full penetrance, 
and slightly more than half would want the HCP to do so if 
the condition were nonfatal and treatable with 50% penetrance. 
The authors also asked 607 students in Norway, where the law 
forbids disclosure without consent. Possibly because of the 
law, a smaller but still substantial proportion (approximately 
20%) wanted HCPs to inform them of each type of condition. 
Notably, in another study (United Kingdom),23 a patient who 
found out about his HD risk when a sibling was diagnosed was 
angry because distant relatives already knew about the risk. He 
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thought that health services should have mechanisms to warn 
people but recognized that implementation would be difficult.
HCPs generally felt some responsibility to relatives
In two qualitative studies (the Netherlands and the United 
Kingdom),26,41 HCPs briefly discussed having a moral respon-
sibility to relatives. More specific data came from a study with 
genetic counselors and clinical geneticists (United States),34,35 in 
which 63% (161/257) and 69% (143/206), respectively, said they 
perceived an obligation.
Two studies with nongenetic HCPs also showed that they felt 
a responsibility to patients’ relatives, including family physi-
cians (United States)36 who, on average, did not think they had 
a legal “duty to contact” but would be morally justified in doing 
so, particularly with treatable conditions. Of 155 pediatricians 
and obstetricians/gynecologists in Turkey who considered the 
scenario of a patient refusing to tell his siblings and wife about 
his balanced translocation diagnosis, most (78.5%) agreed that 
they should inform the spouse.39 A smaller majority (41.2%) 
agreed that HCPs should tell siblings, with the remainder 
divided evenly between “disagree” and “neutral.” The majority 
(58.3%) disagreed that they should respect the patient’s deci-
sion. Family doctors in Slovenia38 considered the scenario of a 
35-year-old refusing to tell his 30-year-old brother (also their 
patient) about a hypertrophic obstructive cardiomyopathy risk. 
Of 271 doctors, 73.9% would directly inform and only 34.1% 
would respect patient wishes. In both studies, more occupa-
tional experience significantly predicted the decision to inform. 
Occupation could also explain why more clinical geneticists 
than genetic counselors stated they would warn in the US 
studies.34,35
Fewer (but still a substantial number of) nurses working out-
side genetics37 felt they should “take steps to inform” relatives if 
a patient refused to do so (17.8% fragile X; 30.1% breast cancer; 
24.7% HD). However, for each condition, approximately 85% 
also agreed that they should respect confidentiality—meaning 
that some answered “agree” to both questions, a contradiction 
that the authors did not explain. 
HCPs only sometimes acted on this responsibility
Four studies discussed nondisclosure frequency (albeit relying 
on HCPs’ subjective reports). A prospective survey33 across 12 
UK and 2 Australian centers showed only 65 nondisclosures 
of nearly 40,000 genetic clinic consultations (<1%) in 1 year. 
Most were for HD, translocations, and hereditary breast/ovar-
ian cancer or colorectal cancer; 39 were to adult children, 22 to 
siblings, and 4 to current or former partners at risk of having 
affected children. No HCPs disclosed without permission, but 
the authors did not report the reasons. In another UK study,41 
genetic HCPs were not specifically asked about disclosure 
dilemmas, but two reported sharing genetic information with 
patients’ offspring without consent.
Two US studies reported higher nondisclosure rates. In one,35 
60% (123/206) of clinical geneticists reported patients who 
refused to disclose at least once (mostly translocations and 
“genetic syndromes”). Some individuals reported more than 16 
instances of nondisclosure. Unlike in the UK/Australia study,33 
25% (31/123) considered informing relatives without explicit 
consent, and 4 of the 31 did so; how they did so was unreported. 
In the other US study34 with genetic counselors, 46% (119/250) 
reported experiencing refusals (mostly involving translocations 
and inherited cancer risks). Twenty-two (18%) considered dis-
closing without consent, but only one did, because the relative 
was her patient and the result was negative. Neither US study 
reported which relatives patients refused to tell or the time-
frames in which these nondisclosures took place. 
Arguments for acting/not acting on responsibility
Participants expressed several overlapping ethical, social, and 
practice-related arguments for and against HCPs acting on their 
responsibility (e.g., by sharing information). Some arguments 
also help to explain why some HCPs did not perceive a respon-
sibility in the first place. We have listed arguments in decreasing 
order of the number of studies that raised them (except the first, 
which we place there because it encompasses other arguments). 
In parentheses, we show which group(s) discussed each.
1. (Mis)interpretations of guidelines and the law (HCPs/
patients)
Five studies reported that participants had misconceptions 
about guidelines and/or the law, and some authors discussed 
how awareness, or lack thereof, possibly influenced views. For 
example, Stol et al.26 thought misinterpretations would pre-
vent HCPs taking action when they could. In their study, some 
clinical geneticists believed the population-screening act dis-
allowed unsolicited contact with patients’ relatives. However, 
clinical genetic practice falls outside this legislation; HCPs can 
legally inform relatives of risks without patient consent. From 
the opposite perspective, Barnoy and Tabak (Israel)37 thought 
that a lack of understanding of Israeli law (which takes a rela-
tively individualist stance) explained why some nurses said they 
would take steps to inform relatives if patients refused.
In the United States, 24% (61/253) of genetic counsel-
ors34 and 66% (146/206) of clinical geneticists35 erroneously 
believed that federal guidelines regulate disclosure. Also incor-
rectly, 35% (89/254) of genetic counselors and 29% (60/206) 
of clinical geneticists thought the National Society of Genetic 
Counsellors and the American College for Medical Genetics 
and Genomics, respectively, have specific guidelines for disclo-
sure without consent. Less than half of both groups (44% of 
genetic counselors; 38% of clinical geneticists) were aware of 
American Society of Human Genetics and Genomics guide-
lines, which permit disclosure in certain circumstances. The 
authors suggest that this knowledge dearth might explain why 
so few disclosed in situations where guidelines would permit 
disclosure, but also that those aware might not feel obliged 
to warn because guidelines do not provide specific mandates 
to do so. Stol et al.26 also cited the lack of specific legislation 
or guidance as a reason for geneticists’ confusion. Liability 
was a related concern in the United States and the United 
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Kingdom,34,35,41 and some HCPs in the United Kingdom wor-
ried that certain situations did not meet the General Medical 
Council’s “serious harm” criteria.11
Patients also held misconceptions—one thought that dis-
closure without consent would violate Canada’s “privacy of 
information protection act” (no such act exists).27 By contrast, 
patients in one US study28 said that it was important that HCPs 
disclose despite concerns about liability.
2. Privacy
2i. Disclosure puts privacy in jeopardy (HCPs/patients)
Clinical geneticists and genetic counselors (United 
Kingdom and United States) 34,35,41 were reluctant to disclose 
to relatives because they thought patients saw information 
as private and because laws protected privacy. Indeed, the 
clinical geneticists who faced disclosure dilemmas ranked 
respect for patient confidentiality as the most important con-
sideration in decisions not to disclose. Similarly, most (62%) 
pediatricians and obstetricians/gynecologists (Turkey)39 
said they thought genetic information belongs to indi-
viduals rather than family or humanity in general. Clinical 
geneticists (United States)35 also thought that protecting 
privacy is integral to doctor–patient relationships. A few 
patients (Canada)27 agreed that HCPs could damage these 
relationships by disclosing. Patients corroborated that they 
saw genetic information as private: it was the main reason 
that 22/30 patients in Israel30 intended not to tell relatives 
of prenatal/hereditary cancer risks (although the perceived 
meaning of genetic information was unclear). In addition to 
patient privacy, clinical geneticists in the Netherlands26 wor-
ried about invading relatives’ privacy by disclosing, and one 
patient in Canada27 also raised this issue. They thought some 
relatives might not want to know about risk and patients 
would be better at making these distinctions.
2ii. Privacy is easily trumped (HCPs/patients)
While considering genetic information as being private to 
individuals, patients in Canada and the United States27,28 also 
thought that privacy should not trump others’ right to know 
relevant information, particularly when it could prevent ill-
ness or death, and when breaching a single person’s confiden-
tiality could help many people. This view reflected a utilitarian 
approach, i.e., maximizing benefit.
Some patients in Turkey39 did not think of genetic informa-
tion as private to the individual: of 104, most (49%) thought 
it belongs to “the family,” aligning with the joint-account 
model, and some (12%) thought it belongs to “humanity.” 
Fewer (39%) answered “individuals.” Patients and HCPs who 
thought that information is familial were significantly more 
likely to agree that doctors should share if patients refuse. In 
fact, at least 60.5% of those who considered genetic informa-
tion individual also thought doctors should share. The fact 
that the family unit is “the most important primary and inti-
mate unit”39 in Turkish society may explain why genetic infor-
mation was considered familial in this study, but discerning 
the role of culture was difficult because other authors did 
not ask similar questions. Nevertheless, some patients in the 
United States28 made more specific distinctions between indi-
vidual and familial information. They thought relatives have 
a right to know general information (the “genetic alteration,” 
as phrased by one patient) and sharing it would not consti-
tute a breach, but they also thought relatives do not have a 
right to know specific patient results or the patient’s identity. 
They said HCPs can be trusted to make this distinction and 
share accordingly but that relatives might not always do so 
(e.g., would probably reveal patient identities), thus thinking 
that HCP disclosure would better protect privacy.
3. Medical benefit
3i. Medical benefit to relatives outweighs harm of breach 
(HCPs/patients)
In US studies, clinical geneticists34 and genetic counselors35 
who experienced disclosure dilemmas rated medical benefit as 
highly influential in decision making, specifically with respect 
to the relative’s age, the risk magnitude, treatability, manage-
ability, and early monitoring.
Treatability and relative’s age were also important consider-
ations for nongenetic HCPs. A higher proportion of nurses in 
Israel37 said that they would take steps to inform relatives about 
hereditary breast cancer risks (where intervention is available) 
than about fragile X or HD. Given a scenario involving nondis-
closure by a man to his children, 165 family physicians (United 
States)36 were, on average, unsure whether children should be 
informed about the risk of a potentially fatal condition but 
tended to favor disclosure more—particularly with older chil-
dren (22-year-olds versus 17-year-olds)—if the condition was 
treatable rather than nontreatable.
Two studies (among family physicians in Slovenia38 and pedi-
atricians and obstetricians/gynecologists in Turkey39) did not 
explicitly discuss medical benefit, but both used dilemma sce-
narios in which the conditions had available interventions. This 
possibly influenced the majority decision to disclose observed 
in these studies.
3ii. Determining medical benefit is complex (HCPs)
A minority of HCPs queried the “medical benefit” justifi-
cation. Clinical geneticists in the Netherlands26 questioned 
whether interventions were beneficial. They explained that 
hereditary cancer screening had “unproven qualities” and 
preventative options were “extremely drastic, if not dra-
conian.” They nevertheless thought it was “fair to inform 
people” but implied that HCPs should make these limita-
tions explicit. A genetic consultant in a UK study41 noted that 
interventions need not be medical. She said that knowing was 
“almost like having an intervention” and did not think that 
“having an intervention makes such a difference.” On this 
basis, she told the symptomatic offspring of a patient with 
HD (in the absence of familial communication) that they 
were at risk. Notably, in a study with the Swedish public,31 
more than half said they would want HCPs to inform them, 
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even against relatives’ wishes, about fatal conditions with no 
available intervention—although these hypothetical views 
might not match actual decisions.
4. Family dynamics
4i. HCP disclosure can damage family dynamics (HCPs)
Genetic counselors (United States)34 who had faced dis-
closure dilemmas considered patient–relative relationships 
and patients’ emotional reactions two of the most influential 
considerations in their decisions about whether to disclose. 
In comparison, clinical geneticists (United States)35 who faced 
disclosure dilemmas focused less on social/emotional issues 
but still rated patient–relative relationships as the most impor-
tant nonmedical consideration. These HCPs as well as those 
in a study by Clarke et al. (United Kingdom/Australia)33 per-
ceived patient noncommunications as being due mostly to 
familial issues (estrangement, difficult relationships, and pro-
tecting relatives). Indeed, patients in a Canadian study27 gave 
such reasons for noncommunication. HCPs might have felt 
worried that they could exacerbate these perceived problems 
by disclosing information.
4ii. HCP disclosure can help family relationships (HCPs)
HCPs in a UK study41 argued that secrets could cause resent-
ment and, by informing relatives when patients refuse, they 
could encourage open communication within families and 
consequently help relatives maintain close relationships and 
support one another, which the author argued is particularly 
important when facing difficult medical decisions. This view, 
reflecting a relational approach to autonomy, may have been 
influenced by the guidelines of the British Society for Genetic 
Medicine,13 which encourage HCPs to take disclosure rather 
than confidence as the default position. 
5. HCPs can communicate better than patients and relatives 
(HCPs and patients)
Although patients, in general, said they preferred that rela-
tives, rather than HCPs, tell them about risk, some argued that 
HCPs would be more reliable communicators. For example, 
some said HCPs would communicate facts more accurately and 
could more easily surmount obstacles of geographical distance, 
“social/emotional distance,” and “fragile family relationships.”28
In studies in the United States35 and the Netherlands,26 clini-
cal geneticists said that patients might have inadequate knowl-
edge about who was at risk. In the latter study, however, they 
also thought that patients would be better able to consider the 
possible psychological harms of disclosure as well as to judge 
which relatives would benefit from knowing and which might 
not cope well emotionally (although this might be the case only 
when the patient wants to disclose and the family are close). 
HCPs also thought it would be too problematic to disclose 
directly to patients’ relatives because of lack of contact details 
and insufficient time, money, and staff.
6. Respecting (individual) autonomy (HCPs)
Clinical geneticists in the Netherlands26 worried that they 
would appear directive and relatives would feel pressured into 
being tested if they, rather than other family members, told 
them about their risk and options. They argued that they should 
remain nondirective, e.g., about whether patients should tell rel-
atives, and whether relatives should undergo testing. However, 
others said patients could also pressure relatives into testing, 
highlighting the difficulty in ensuring that those being tested 
are making autonomous decisions.
Conclusions in the reviewed studies
Only four papers offered a conclusion as to what HCPs should 
do when facing disclosure dilemmas: three (from within and 
outside genetics, in Turkey, the United Kingdom, and the 
Netherlands)26,39,41 suggested that HCPs could justifiably inform 
relatives when patients fail to do so, and one (outside genetics, 
in Israel)37 suggested that HCPs should continue to empha-
size patient autonomy and privacy. Most (n = 8) concluded 
that guidelines should be refined to better address dilem-
mas,22,30,34–36,38–40 although two advocated leaving room for inter-
pretation so that HCPs could treat dilemmas on a case-by-case, 
rather than routine, basis.23,33
DISCUSSION
This synthesis provides insight into perspectives on HCPs’ 
responsibility to patients’ relatives and HCP disclosure. HCPs 
generally felt responsible for relatives but perceived several 
obstacles to acting on this responsibility. The public and patients 
regarded HCP disclosure as unfavorable in approximately half 
the studies. In six competing and overlapping arguments, par-
ticipants discussed the harms and benefits of disclosure by 
HCPs (summarized in Figure 2). Most arguments were drawn 
from HCP studies: public/patient views were underexplored. 
Limitations of the reviewed studies (including heterogeneity in 
Figure 2 Summary of arguments. HCP, health-care professional.
Harms
Patient privacy Privacy can be maintained
Medical benefit
Family dynamics
HCPs’ better at communicating
Relatives’ privacy
Medical benefit hard to define
Family dynamics
Patient autonomy
Benefits
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populations and use of hypothetical scenarios) make our syn-
thesis tentative, and its findings are in need of further consider-
ation and research. Therefore, we turn to the wider literature to 
examine barriers to disclosure that HCPs might overcome and 
which arguments need more interrogation.
Patients in our review thought that HCPs should protect 
patient privacy and maintain confidential doctor–patient 
relationships by not disclosing. They also said that unsolicited 
contact with relatives could invade their privacy. However, 
relatives directly contacted by HCPs through registries have 
not felt that HCPs invaded their privacy and, although anx-
ious about the news, were pleased to be informed.15,19 Indeed, 
in our review, participants generally thought privacy was less 
important than the opportunity to prevent serious illness or 
death. Moreover, when patients were asked to consider pri-
vacy in more detail, they said “genetic information” was famil-
ial and that HCPs could protect privacy and confidentiality by 
sharing de-identified information. These nuanced views were 
explored in only two studies and merit further research, par-
ticularly because “genetic information” can be an ambiguous 
phrase and it is not clear what “levels” of information (e.g., 
general information about familial risk/specific mutation/
patient’s individual result) participants considered private. 
More research is also needed about privacy in the genomic 
medicine context, in which most studies have focused on 
concerns about researchers, insurers, and employers access-
ing sequence data, rather than patients’ willingness to share 
genomic information with family.42 However, in one study 
with 563 parents of children undergoing sequencing, only 
5.2% thought that results should not be shared with relatives, 
and 93 and 88% perceived a right to be informed if a sibling’s 
genome sequence showed a familial risk of a serious treatable 
or nontreatable condition, respectively,43 suggesting favorable 
views of information sharing.
Family dynamics was another important consideration for 
HCPs, who were concerned that HCP disclosure could have 
a negative impact. In the wider literature, patients telling rela-
tives about genetic risk/diagnoses reported feeling blamed or 
that relationships had become hostile.44 The same might occur 
if HCPs shared information about a patient whose identity 
was obvious. However, in some cases HCP disclosure when a 
patient has refused might be better for family dynamics than 
respecting patient wishes not to share, given that secrets and 
disclosure delays were shown in our review,23,41 as well as in 
other research,29,44,45 to damage relationships and cause disap-
pointment and resentment. Relatives unaware of risk might also 
eventually question why HCPs had not told them.46 By contrast, 
good communication about genetic risks could bring families 
closer together.44 Again, HCPs sharing general rather than spe-
cific information might protect individual patients from blame, 
although patient identity might sometimes be obvious.
A related concern was that HCPs did not want to be directive 
in telling patients to disclose, but it has been suggested that non-
directiveness is not appropriate for all aspects of genetic consul-
tations/counseling.47 Arguably, accepting patients’ decisions not 
to tell relatives is based on an overly simplistic understanding 
of what an “autonomous decision” is, and HCPs should direct 
patients away from decisions they might later regret or that put 
relatives at harm.48
Several studies reported that HCPs lacked awareness of, 
or had misinterpreted, guidelines or the law. The influence 
of guidelines was ambiguous. HCPs aware of them might be 
either more likely to disclose (because they know it is permit-
ted) or less likely to disclose (because they worry the situation 
does not fit the criteria for which disclosure is permitted or 
because guidelines do not mandate disclose). Eight papers con-
cluded that HCPs need clearer guidelines and policies on han-
dling disclosure dilemmas and appropriate sharing, although 
our synthesis suggests that this may not help, because HCPs 
do not always know what the guidelines or relevant law says. 
Professional practice norms and personal values may also have 
influenced the attitudes of HCPs and are worth delineating in 
future research.
None of the reviewed studies addressed what action HCPs 
could take if erring on the side of disclosure and whether such 
an approach would be practical, especially when resources are 
constrained and little or no reimbursement is made for time 
spent counseling patients’ relatives.49  Resources are likely to 
suffer additional strain as HCPs more frequently use whole-
exome sequencing/whole-genome sequencing; although 
sequencing cost is decreasing, interpretation remains difficult 
and expensive.50
Involving family members, at least in the initial stages of clin-
ical integration of genomic medicine, will be crucial. Uncertain 
results from a genome sequence will sometimes require HCPs 
to test relatives to clarify meaning. Moreover, incidental find-
ings (e.g., BRCA1 gene mutation in a boy with developmen-
tal delay) might be more relevant to relatives’ health than to 
patients’ health.51 These issues reinforce the importance of 
exploring HCPs’ responsibility to relatives and whether, when, 
and to whom HCPs should disclose information.
Recommendations
Although further research is needed, we recommend that:
1. Clinical practice reflect the fact that privacy is nuanced 
and HCPs can sometimes share genetic information with-
out breaching confidentiality
2. Researchers define and make distinctions between lev-
els of “genetic information” when seeking HCPs’ and 
patients’ views about privacy
3. HCPs factor into their considerations about disclosure the 
potential harm to family dynamics of nondisclosure and 
potential benefit of HCP disclosure, even when patients 
are withholding information
4. Researchers, policy-makers, and HCPs do not rely 
solely on published guidelines to help resolve disclosure 
dilemmas
5. Further research be conducted regarding practical ways 
for HCPs to share information, how HCPs can resolve 
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competing interests within potentially dysfunctional 
families,52,53 and attitudes toward sharing informa-
tion with family members in the context of genomic 
medicine
CONCLUSIONS
In this synthesis, we have shown that, although HCPs generally 
felt a responsibility toward relatives, concerns including pri-
vacy and family dynamics prevented them from acting on this 
responsibility. Yet we also showed that HCPs can sometimes 
share information without intruding on privacy and that shar-
ing might facilitate family dynamics. We argue that norms in 
genetic medicine warrant reconsideration, especially as more 
genome tests are used. We thus call for more nuanced research 
about familial and individual approaches that facilitates the 
clinical integration of genomic health care to enhance familial, 
not just individual, benefit.
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